Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28944303 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL22636129 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL800319 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL4802204 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL29634909 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL30532495 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL29779377 | 1.00 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL3308417 | 0.98 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL22648502 | 0.98 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL17356388 | 0.98 | ACE (0.45) | ACEMEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110776558-B | Method for solid-phase synthesis of actibant acetate | 江苏豪森药业集团有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-111944016-B | Preparation method of icatibant acetate | 台州吉诺生物科技有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-4695268-A1 | ANTIBACTERIAL COVALENT PEPTIDE INHIBITORS | Université de Bordeaux (FR) | 2026-02-18 | — | — | EP | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240368215-A1 | METHOD AND APPARATUS FOR PRODUCING PEPTIDE | YOKOGAWA ELECTRIC CORPORATION (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-4458460-A1 | METHOD AND APPARATUS FOR PRODUCING PEPTIDE | Yokogawa Electric Corporation (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| US-11420997-B2 | Peptide synthesis method | JITSUBO CO., LTD. | 2022-08-23 | — | — | US | disclosed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022096394-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | disclosed |
| CN-111944016-B | Preparation method of icatibant acetate | 台州吉诺生物科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220050107-A1 | NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | ACE 22/4885MEN1 537/4885KMT2A 4690/4885 |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | ACE 1694/4885MEN1 268/4885KMT2A 3979/4885 |
| US-20240368215-A1 | METHOD AND APPARATUS FOR PRODUCING PEPTIDE | VIP, ANPEP, NPPA | ACE 380/4885MEN1 1967/4885KMT2A 3997/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ACE 831/4885MEN1 492/4885KMT2A 3145/4885 |
| US-11420997-B2 | Peptide synthesis method | NPPA, ANPEP, VIP | ACE 824/4885MEN1 1827/4885KMT2A 3246/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ACE 831/4885MEN1 492/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.